On this teleconference, Rudy Tanzi provides an overview on the genetics of Alzheimer's and an update on new research approaches. He then answers questions, many of which come from members of the research community.
Here are some abstracts with relevance to biotechs that I noted - let me know if I've missed any:
(KERX): Abstract #LBA3501: Results of the X-PECT study: A phase III randomized double-blind placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). (J. C. Bendell)
(EXEL) Abstract #5508: An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. (P. Schoffski)
(AVEO) Abstract #CRA4501: Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial. (R. J. Motzer)
(MDVN) Abstract #4519: Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor. (J. S. De Bono)
(CELGZ) Abstract #CRA1002: CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). (H. S. Rugo)
(IMGN) Abstract #LBA1: Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. (K. L. Blackwell)
(ARIA) Abstract #6503: PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. (J. E. Cortes)
(PCYC)Abstract #6507: The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study. (J. C. Byrd)
The dates reflected on your post indicates July, 2012, but isn't the annual ASCO meeting taking place June 1-5th in Chicago. What is the difference in dates? Is this a separate ASCO meeting and wouldn't these companies present at the June conference for better exposure?
This is the "Best of ASCO" program where they select some of the best abstracts to be presented at ASCO and discuss them in other cities like Chicago and Boston at a later date. Sort of a mini-ASCO for folks that can't travel to the real thing.
too much betacarotene, even if solely through diet, may be harmful...
RESEARCHERS FIND POTENTIAL ‘DARK SIDE’ TO DIETS HIGH IN BETA-CAROTENE COLUMBUS, Ohio - New research suggests that there could be health hazards associated with consuming excessive amounts of beta-carotene.